person · Reporting owner
Litchev Boyan Vesselinov
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Chief Medical Officer | January 31, 2022 | December 20, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indaptus Therapeutics, Inc.
Report date January 31, 2022 · Filed December 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,150 |
Ending reported balance
After 2022-12-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-01-31 · Purchase · Acquired 100 · Balance 100 Row 2 · 2022-03-02 · Purchase · Acquired 50 · Balance 150 Row 3 · 2022-11-22 · Purchase · Acquired 500 · Balance 650 Row 4 · 2022-12-01 · Purchase · Acquired 500 · Balance 1,150 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2022 Filed Dec 20, 2022 02:06 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon Stock | 500 | $1.87 | $935.45 |
DisclosureSEC source: 0001493152-22-035926 · ownership.xml · nonDerivative · entry 4 Litchev Boyan Vesselinov · CIK 0001902726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Read SEC document |
| November 22, 2022 Filed Dec 20, 2022 02:06 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon Stock | 500 | $1.83 | $915.00 |
DisclosureSEC source: 0001493152-22-035926 · ownership.xml · nonDerivative · entry 3 Litchev Boyan Vesselinov · CIK 0001902726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Read SEC document |
| March 02, 2022 Filed Dec 20, 2022 02:06 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon Stock | 50 | $4.09 | $204.63 |
DisclosureSEC source: 0001493152-22-035926 · ownership.xml · nonDerivative · entry 2 Litchev Boyan Vesselinov · CIK 0001902726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 00:08 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001493152-22-003030 · ownership.xml · derivative · entry 1 Litchev Boyan Vesselinov · CIK 0001902726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on February 1, 2023 and thereafter the remaining shares vest and become exercisable in equal monthly installments over the following 24 months. Read SEC document |
| January 31, 2022 Filed Dec 20, 2022 02:06 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon Stock | 100 | $4.65 | $465.00 |
DisclosureSEC source: 0001493152-22-035926 · ownership.xml · nonDerivative · entry 1 Litchev Boyan Vesselinov · CIK 0001902726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.